BMS halts hep C trial after 'serious safety issue'
12:20 EDT 2 Aug 2012 | SCRIP
Bristol-Myers Squibb has suspended a Phase II study of its experimental hepatitis C drug BMS-094 because of "a serious safety issue". BMS-094 (formerly known as INX-189), a nucleotide polymerase (NS5B) inhibitor, was the driver behind.....
Original Article: BMS halts hep C trial after 'serious safety issue'
More From BioPortfolio on "BMS halts hep C trial after 'serious safety issue'"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
